伊立替康联合顺铂治疗宫颈癌患者疗效及对血清Bcl—2的影响研究(1)
[摘要]目的 探讨伊立替康联合顺铂治疗宫颈癌患者疗效及对血清Bcl-2的影响。方法 将2015年1月~2016年1月在我院收治的124例宫颈癌患者随机分为观察组(62例)和对照组(62例),观察组采用伊立替康联合顺铂治疗方案,对照组采用紫杉醇治疗方案,比较两组疗效以及对血清Bcl-2的影响。结果 观察组总有效率为80.65%,明显高于对照组的25.81%,差异有统计学意义(P<0.05);两组治疗后Bcl-2蛋白表达水平较治疗前均明显降低,且观察组治疗后Bcl-2蛋白表达水平明显低于对照组,差异有统计学意义(P<0.05)。结论 伊立替康联合顺铂治疗宫颈癌患者有助于降低血清Bcl-2水平,疗效显著,可在临床上推广。
[关键词]宫颈癌;伊立替康;顺铂;B淋巴细胞瘤-2基因
[中图分类号] R737.33 [文献标识码] A [文章编号] 1674-4721(2016)07(b)-0075-03
[Abstract] Objective To investigate the efficacy of irinotecan combined with cisplatin in the treatment of patients with cervical cancer and its effect on serum Bcl-2.Methods 124 cases of cervical cancer patients in our hospital from January 2015 to January 2016 were randomly divided into observation group (62 cases) and control group (62 cases) ......
您现在查看是摘要页,全文长 3942 字符。
[关键词]宫颈癌;伊立替康;顺铂;B淋巴细胞瘤-2基因
[中图分类号] R737.33 [文献标识码] A [文章编号] 1674-4721(2016)07(b)-0075-03
[Abstract] Objective To investigate the efficacy of irinotecan combined with cisplatin in the treatment of patients with cervical cancer and its effect on serum Bcl-2.Methods 124 cases of cervical cancer patients in our hospital from January 2015 to January 2016 were randomly divided into observation group (62 cases) and control group (62 cases) ......
您现在查看是摘要页,全文长 3942 字符。